Lindsay, Alistair
May 2010
Heart;May2010, Vol. 96 Issue 10, p811
Academic Journal
The article discusses the findings of a study on the comparison of the safety and efficacy of second-generation everolimus and paclitaxel-eluting stents in real-life practice.


Related Articles

  • Everolimus-eluting stents the most "economically attractive" option.  // PharmacoEconomics & Outcomes News;7/7/2012, Issue 657, p5 

    The article discusses research on the cost effectiveness of everolimus- compared with paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization by A. P. Amin and colleagues published in the May 29, 2012 issue of the "American Journal of Cardiology."

  • ZOMAXX II.  // Herz;Jul2008, Vol. 33 Issue 5, p383 

    No abstract available.

  • Colocalized Delivery of Rapamycin and Paclitaxel to Tumors Enhances Synergistic Targeting of the PI3K/Akt/mTOR Pathway. Blanco, Elvin; Sangai, Takafumi; Wu, Suhong; Hsiao, Angela; Ruiz-Esparza, Guillermo U; Gonzalez-Delgado, Carlos A; Cara, Francisca E; Granados-Principal, Sergio; Evans, Kurt W; Akcakanat, Argun; Wang, Ying; Do, Kim-Anh; Meric-Bernstam, Funda; Ferrari, Mauro // Molecular Therapy;Jul2014, Vol. 22 Issue 7, p1310 

    Ongoing clinical trials target the aberrant PI3K/Akt/mammalian target of rapamycin (mTOR) pathway in breast cancer through administration of rapamycin, an allosteric mTOR inhibitor, in combination with paclitaxel. However, synergy may not be fully exploited clinically because of distinct...

  • Long-term clinical outcomes of everolimus-eluting stent versus paclitaxel-eluting stent in patients undergoing percutaneous coronary interventions: a meta-analysis. Min Meng; Bei Gao; Xia Wang; Zheng-gang Bai; Ri-na Sa; Bin Ge; Meng, Min; Gao, Bei; Wang, Xia; Bai, Zheng-Gang; Sa, Ri-Na; Ge, Bin // BMC Cardiovascular Disorders;2/9/2016, Vol. 16, p1 

    Background: Everolimus -eluting stent (EES) is common used in patients undergoing percutaneous coronary interventions (PCI). Our purpose is to evaluate long-term clinical outcomes of everolimus -eluting stent (EES) versus paclitaxel-eluting stent (PES) in patients undergoing...

  • Paclitaxel and cyclosporine A show supra-additive antiproliferative effects on smooth muscle cells by activation of protein kinase C. Sindermann, Jürgen R.; Skaletz-Rorowski, Adriane; Bartels, Anke; Hohage, Helge; Plenz, Gabriele; Schmidt, Annette; Breithardt, Günter // Basic Research in Cardiology;Mar2002, Vol. 97 Issue 2, p125 

    We intended to establish a pharmacologic concept of synergistic antiproliferative effects on smooth muscle cells (SMC) by using paclitaxel and cyclosporine A at clinically applicable doses. Coronary SMC were incubated with paclitaxel and cyclosporine A at concentrations of 10 – 20 nmol/L...

  • CXCL12 expression by healthy and malignant ovarian epithelial cells. Machelon, Véronique; Gaudin, Françoise; Camilleri-Broët, Sophie; Nasreddine, Salam; Bouchet-Delbos, Laurence; Pujade-Lauraine, Eric; Alexandre, Jerôme; Gladieff, Laurence; Arenzana-Seisdedos, Fernando; Emilie, Dominique; Prévot, Sophie; Broët, Philippe; Balabanian, Karl // BMC Cancer;2011, Vol. 11 Issue 1, p97 

    Background: CXCL12 has been widely reported to play a biologically relevant role in tumor growth and spread. In epithelial ovarian cancer (EOC), CXCL12 enhances tumor angiogenesis and contributes to the immunosuppressive network. However, its prognostic significance remains unclear. We thus...

  • Boston Scientific launches Promus, Taxus in India.  // Medical Device Daily;2/18/2011, Vol. 15 Issue 34, p1 

    The article deals with the Promus Element everolimus-eluting coronary stent system and Taxus Element paclitaxel-eluting coronary system stent launched by Boston Scientific in India. The systems reportedly use the same novel platinum chromium alloy, stent design and advanced catheter delivery...

  • TCT Notebook.  // Medical Device Daily;9/25/2009, Vol. 13 Issue 185, p7 

    This article deals with the one-year data reported by Boston Scientific from a trial that compared the Xiance V everolimus-eluting coronary stent system with the Taxus Express paclitaxel-eluting coronary stent system. 3,690 patients served as subjects in this study, which highlighted the...

  • Antineoplastics.  // Reactions Weekly;1/17/2009, Issue 1235, p8 

    The article describes the case of a 53-year-old man receiving ciclosporin as immunosuppression after a renal transplant. The patient experienced diarrhoea, neutropenia and ciclosporinaemia after receiving carboplatin and paclitaxel for metastatic pulmonary adenocarcinoma. An absence of any...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics